COVID-19 核酸擴增測試 (NAAT) 市場：管道報告2023 年最新版

NAAT 標靶並擴增 SARS-CoV-2 病毒的特定核酸序列。與抗原鑑定方法相比，NAAT 顯示出更高的靈敏度。PCR 中使用多個目標來檢測不同類型的 SARS-Cov-2。

本報告調查了COVID-19核酸擴增測試（NAAT）市場，提供了產品概述、正在開發的管道產品的趨勢、處於不同開發階段的產品的比較分析、正在進行的臨床試驗的資訊以及參與公司的資訊。我們提供有關最新趨勢等的資訊。

目錄

第一章 內容

第 2 章 簡介

第三章 開發中產品

• COVID-19 核酸擴增檢驗 (NAAT) - 按開發階段劃分的管道產品
• COVID-19 核酸擴增檢驗 (NAAT) - 區域管線產品
• COVID-19 核酸擴增測試 (NAAT) - 按監管途徑分類的管道產品
• COVID-19 核酸擴增檢驗 (NAAT) - 正在進行的臨床試驗

第 4 章 COVID-19 核酸擴增檢驗 (NAAT) - 公司正在開發的管道產品

• COVID-19 核酸擴增檢測 (NAAT) 公司 - 按開發階段劃分的在研產品
• COVID-19 核酸擴增檢驗 (NAAT) - 按開發階段劃分的管道產品

第五章 COVID-19 核酸擴增檢測（NAAT）公司與產品概述

• Age Labs AS 公司簡介
• Chengdu One-Chip Biotechnology Co Ltd公司簡介

第 6 章 COVID-19 核酸擴增檢測 (NAAT) - 最新進展

第7章附錄

Abstract

GlobalData's Medical Devices sector report, "COVID 19 Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" provides comprehensive information about the COVID 19 Nucleic Acid Amplification Tests (NAATs) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

NAAT involves amplification of specific nucleic acid sequences of SARS-CoV-2 virus by targeting specific nucleic acid sequences. NAAT exhibits better sensitivity in comparison to antigen identification methods. Multiple targets are used in PCR to detect the different types of SARS-Cov-2.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

• Extensive coverage of the COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of COVID 19 Nucleic Acid Amplification Tests (NAATs) and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Overview

3 Products under Development

• 3.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• 3.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
• 3.3 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
• 3.4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials

4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products under Development by Companies

• 4.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
• 4.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development

5 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies and Product Overview

• 5.1 Age Labs AS Company Overview
  • 5.1.1 Age Labs AS Pipeline Products & Ongoing Clinical Trials Overview
• 5.2 Chengdu One-Chip Biotechnology Co Ltd Company Overview
  • 5.2.1 Chengdu One-Chip Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

6 COVID 19 Nucleic Acid Amplification Tests (NAATs)- Recent Developments

• 6.1 Nov 29, 2023: BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer
• 6.2 Oct 30, 2023: Cepheid Receives 510(K) Clearance For Xpert Xpress CoV-2 Plus Test
• 6.3 Mar 17, 2023: When time matters, rapid point of care testing can support treatment decisions
• 6.4 Mar 15, 2023: Cepheid receives Health Canada Licence for Xpert Xpress CoV-2 plus

7 Appendix

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us
• 7.4 Disclaimer

List of Tables

List of Tables

• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials
• COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• Glossary

List of Figures

List of Figures

• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials